​

Haemonetics (HAE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HAE Stock Forecast

Haemonetics (HAE) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $108.25, with a high of $120.00 and a low of $85.00. This represents a 51.70% increase from the last price of $71.36.

$70 $80 $90 $100 $110 $120 High: $120 Avg: $108.25 Low: $85 Last Closed Price: $71.36

HAE Stock Rating

Haemonetics stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 1 Strong Buy (6.25%), 8 Buy (50.00%), 7 Hold (43.75%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 7 8 1 Strong Sell Sell Hold Buy Strong Buy

HAE Price Target Upside V Benchmarks

TypeNameUpside
StockHaemonetics51.70%
SectorHealthcare Stocks 24.81%
IndustryMedical Instruments & Supplies Stocks25.32%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$107.00
Last Closing Price$71.36$71.36$71.36
Upside/Downside--49.94%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25531-110
May, 25531-110
Apr, 25531-110
Mar, 25531-110
Feb, 25532--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 08, 2024Andrew CooperRaymond James$120.00$74.8360.36%68.16%
Sep 13, 2024Kristen StewartC.L. King$116.00$73.2658.34%62.56%
Sep 11, 2024Craig BijouBank of America Securities$85.00$71.6218.68%19.11%
Jun 12, 2024Mike MatsonNeedham$112.00$83.4134.28%56.95%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 18, 2025NeedhamBuyBuyhold
Nov 08, 2024Raymond JamesStrong Buyupgrade
Sep 11, 2024Bank of America SecuritiesNeutralinitialise
Sep 10, 2024JMP SecuritiesMarket OutperformMarket Outperformhold
Sep 10, 2024BTIGBuyinitialise
Aug 22, 2024NeedhamMarket OutperformMarket Outperformhold
Jun 12, 2024NeedhamHoldBuyupgrade
May 10, 2024JMP SecuritiesMarket OutperformMarket Outperformhold
May 10, 2024JMP SecuritiesOutperformOutperformhold
Jun 12, 2023William BlairOutperformOutperformhold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 $8 Mar 21 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28
Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28
Reported$1.57$0.85$2.27$2.32$3.31---
Avg Forecast$2.56$2.53$2.97$3.96$4.59$5.28$6.07$7.55
High Forecast$2.62$2.59$3.02$4.03$4.60$5.36$6.66$7.68
Low Forecast$2.53$2.50$2.92$3.95$4.57$5.20$5.34$7.42
Surprise %-38.67%-66.40%-23.57%-41.41%-27.89%---

Revenue Forecast

$850M $1B $1B $1B $2B $2B Mar 21 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28
Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28
Reported$870.46M$993.20M$1.17B$1.31B$1.36B---
Avg Forecast$868.82M$986.15M$1.15B$1.30B$1.39B$1.44B$1.57B$1.81B
High Forecast$883.98M$1.00B$1.17B$1.31B$1.40B$1.46B$1.57B$1.84B
Low Forecast$859.55M$975.63M$1.14B$1.28B$1.38B$1.41B$1.57B$1.79B
Surprise %0.19%0.71%1.19%1.08%-2.36%---

Net Income Forecast

$-50M $40M $130M $220M $310M $400M Mar 21 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28
Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28
Reported$79.47M$43.38M$115.40M$117.56M$167.68M---
Avg Forecast$89.59M$-3.10M$152.47M$123.81M$235.67M$271.40M$308.39M$388.05M
High Forecast$107.51M$3.75M$155.16M$148.57M$236.44M$275.29M$342.43M$394.89M
Low Forecast$71.67M$-9.95M$149.83M$99.05M$234.90M$267.50M$274.35M$381.33M
Surprise %-11.30%-1498.81%-24.31%-5.05%-28.85%---

HAE Forecast FAQ

Is Haemonetics stock a buy?

Haemonetics stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 8 Buy, 7 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Haemonetics is a favorable investment for most analysts.

What is Haemonetics's price target?

Haemonetics's price target, set by 16 Wall Street analysts, averages $108.25 over the next 12 months. The price target range spans from $85 at the low end to $120 at the high end, suggesting a potential 51.70% change from the previous closing price of $71.36.

How does Haemonetics stock forecast compare to its benchmarks?

Haemonetics's stock forecast shows a 51.70% upside, outperforming the average forecast for the healthcare stocks sector (24.81%) and outperforming the medical instruments & supplies stocks industry (25.32%).

What is the breakdown of analyst ratings for Haemonetics over the past three months?

  • June 2025: 50.00% Strong Buy, 30.00% Buy, 10.00% Hold, 0% Sell, 10.00% Strong Sell.
  • May 2025: 50.00% Strong Buy, 30.00% Buy, 10.00% Hold, 0% Sell, 10.00% Strong Sell.
  • April 2025: 50.00% Strong Buy, 30.00% Buy, 10.00% Hold, 0% Sell, 10.00% Strong Sell.

What is Haemonetics’s EPS forecast?

Haemonetics's average annual EPS forecast for its fiscal year ending in March 2026 is $5.28, marking a 59.52% increase from the reported $3.31 in 2025. Estimates for the following years are $6.07 in 2027, and $7.55 in 2028.

What is Haemonetics’s revenue forecast?

Haemonetics's average annual revenue forecast for its fiscal year ending in March 2026 is $1.44B, reflecting a 5.67% increase from the reported $1.36B in 2025. The forecast for 2027 is $1.57B, and $1.81B for 2028.

What is Haemonetics’s net income forecast?

Haemonetics's net income forecast for the fiscal year ending in March 2026 stands at $271.4M, representing an 61.86% increase from the reported $167.68M in 2025. Projections indicate $308.39M in 2027, and $388.05M in 2028.